Allogene Therapeutics (ALLO) & Its Peers Financial Review
Allogene Therapeutics (NASDAQ: ALLO) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Allogene Therapeutics to similar businesses based on the strength of its risk, valuation, analyst recommendations, earnings, profitability, dividends and institutional ownership.
Earnings & Valuation
This table compares Allogene Therapeutics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Allogene Therapeutics Competitors||$934.72 million||$204.36 million||-1.34|
This table compares Allogene Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Allogene Therapeutics Competitors||-5,041.11%||-62.49%||-26.17%|
This is a breakdown of recent recommendations for Allogene Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Allogene Therapeutics Competitors||809||2698||5966||251||2.58|
Allogene Therapeutics presently has a consensus price target of $35.25, suggesting a potential upside of 34.03%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.68%. Given Allogene Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than its rivals.
Insider & Institutional Ownership
44.9% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Allogene Therapeutics beats its rivals on 6 of the 11 factors compared.
About Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.